Kerin Adelson
Medical Oncology · Houston, TXNPI 1285846790
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,270 of the $20,640 with a category attached, or 74.0%. 7 manufacturers reported payments, led by AstraZeneca at 39.7% of the total. 2022 is the largest year on record at $10,900, 3.8 times the $2,858 reported in 2019.
Across 15 payments — averaging $1375.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- AbbVie$7K
- Roche Molecular Systems, Inc.$3K
- Genentech USA, Inc.$2K
- E.r. Squibb & Sons, L.L.C.$147
- Gilead$12
- plus $11 from 1 others
Across 24 payments — averaging $113,998 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.6M
- Genentech, Inc.$80K
- Radius Health, Inc.$25K
- Astrazeneca UK Limited$13K
- Bayer$6K
- Stemline Therapeutics Inc.$250
What the payments were for
- Consulting fees$15,27074%
- Speaking & faculty fees$5,34726%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $8,200 |
| AbbVie | 3 | $7,425 |
| Roche Molecular Systems, Inc. | 4 | $2,700 |
| Genentech USA, Inc. | 1 | $2,145 |
| E.r. Squibb & Sons, L.L.C. | 1 | $147 |
| Gilead | 1 | $12 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Venclexta$7,425
- DIAGNOSTICS INFORMATION SYSTEMS$2,700
How this compares
$20,640 in reported general payments places this provider in the 70th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.